The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Nonalcoholic Fatty Liver Disease Boosts Cardiovascular Risk, But Lacks Management Plan
May 21st 2013Growing evidence suggests increased cardiovascular risk in patients with nonalcoholic fatty liver disease (NAFLD) - in particular nonalcoholic steatohepatitis (NASN) - but no data exists to support a specific management approach.
Tolvaptan Therapy Produces Good Outcomes in Patients with Heart Failure and Hyponatremia
May 3rd 2013Results from a small retrospective study indicate that treatment with tolvaptan increases sodium concentrations and excretion rhythm without significantly affecting kidney function in patients with refractory hyponatremia and dcompensated heart failure.
FDA Limits Usage, Duration of Hyponatremia Drug Due to Observed Liver Damage Risk
Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.